Unrestricted funding for the in-person Scottsdale RAND Appropriateness Panel meeting was generously provided by Warner-Chilcott, Abbott, and Shire. Unrestricted funding for the BRIDGe group is provided by Abbott, Salix, Shire, UCB, and Warner-Chilcott
Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups†
Article first published online: 15 FEB 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 12, pages 2294–2300, December 2012
How to Cite
Cheifetz, A.S., Melmed, G.Y., Spiegel, B., Talley, J., Devlin, S.M., Raffals, L., Irving, P.M., Jones, J., Kaplan, G.G., Kozuch, P., Sparrow, M., Velayos, F., Baidoo, L., Bressler, B. and Siegel, C.A. (2012), Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups. Inflamm Bowel Dis, 18: 2294–2300. doi: 10.1002/ibd.22920
- Issue published online: 15 NOV 2012
- Article first published online: 15 FEB 2012
- Manuscript Accepted: 24 JAN 2012
- Manuscript Received: 23 DEC 2011
Additional Supporting Information may be found in the online version of this article.
|IBD_22920_sm_SuppTab1.doc||23K||Supporting Table 1. BRIDGe Group: Comparative Effectiveness Research Priorities in Inflammatory Bowel Disease (IBD) Survey|
|IBD_22920_sm_SuppTab2.doc||19K||Supporting Table 2. Areas of CER research|
|IBD_22920_sm_SuppTab3.doc||23K||Supporting Table 3. Top 15 Comparative Effectiveness Research Studies in IBD prior to final point allocation|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.